Gennady Poda

Cited by

	All	Since 2017
Citations	3340	1646
h-index	28	21
i10-index	46	28

420

210

105

315

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202211 10 5 9 15 13 26 17 19 28 23 24 35 51 73 117 135 132 133 160 176 205 239 271 308 319 283 401 63

Public access

View all

18 articles

8 articles

available

not available

Based on funding mandates

Co-authors

Igor V. TetkoBIGCHEM GmbH & Helmholtz MunichVerified email at helmholtz-munich.de
$Vsevolod Y. Tanchuk \ Всеволод Танчук$ Vsevolod Y. Tanchuk \ Всеволод Тан...IBOPC, Інститут біоорганічної хімії та нафтохімії НАН УкраїниVerified email at bpci.kiev.ua
Marvin J MeyersAssociate Professor of Chemistry, Saint Louis UniversityVerified email at slu.edu
Matthieu SchapiraAssociate Professor, University of TorontoVerified email at utoronto.ca
Masoud VedadiUniversity of TorontoVerified email at utoronto.ca
Cheryl ArrowsmithSenior Scientist, Princess Margaret Cancer Centre & Professor of Medical Biophysics, University of TorontoVerified email at uhnres.utoronto.ca
Peter BrownVerified email at mindspring.com
Kong Thong NguyenAtomwiseVerified email at atomwise.com
David ChiovittiSamuel Lunenfeld Research Institute Verified email at lunenfeld.ca
frank sicheriLunenfeld-Tanenbaum Research Institute, Mount Sinai HospitalVerified email at lunenfeld.ca
Ioannis PrassasScientist, Mount Sinai Hospital, Toronto, ONVerified email at utoronto.ca
Eleftherios DiamandisProfessor of Laboratory Medicine and Pathobiology, University of TorontoVerified email at mtsinai.on.ca
david m fergusonProfessor of Medicinal Chemistry University of MinnesotaVerified email at umn.edu
Lionel MoulédousCNRS Researcher (CR1), CRCA (CNRS-UT3), TMBI (Univ. Toulouse)Verified email at univ-tlse3.fr
Daniel DurocherThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and Department of MolecularVerified email at lunenfeld.ca
Girinath G. PillaiScientific Officer, Zastra InnovationsVerified email at nyroindia.org
Werner MewesProfessor of Bioinformatics (retired), Technische Univ. MünchenVerified email at mytum.de
Azza EissaPhD Candidate, University of Toronto Department of Laboratory Medicine and PathobiologyVerified email at utoronto.ca
Yurii SushkoGoogleVerified email at google.com
Vladimir PotemkinSouth Ural State UniversityVerified email at susu.ru

Gennady Poda

PhD, Scientific Advisor & Group Leader, Computational Chemistry and Chemoinformatics, OICR

Verified email at oicr.on.ca

Computational Chemistry Cheminformatics Structure-Based Drug Design In Silico ADMET property prediction Medicinal Chemistry


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds R Mannhold, GI Poda, C Ostermann, IV Tetko Journal of pharmaceutical sciences 98 (3), 861-893, 2009	553	2009
Can we estimate the accuracy of ADME–Tox predictions? IV Tetko, P Bruneau, HW Mewes, DC Rohrer, GI Poda Drug discovery today 11 (15-16), 700-707, 2006	269	2006
Unleashing the therapeutic potential of human kallikrein-related serine proteases I Prassas, A Eissa, G Poda, EP Diamandis Nature reviews Drug discovery 14 (3), 183-202, 2015	206	2015
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia F Grebien, M Vedadi, M Getlik, R Giambruno, A Grover, R Avellino, ... Nature chemical biology 11 (8), 571-578, 2015	188	2015
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) DR Anderson, MJ Meyers, WF Vernier, MW Mahoney, RG Kurumbail, ... Journal of medicinal chemistry 50 (11), 2647-2654, 2007	180	2007
ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions I Sushko, E Salmina, VA Potemkin, G Poda, IV Tetko Journal of chemical information and modeling 52 (8), 2310-2316, 2012	162	2012
Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds IV Tetko, GI Poda Journal of medicinal chemistry 47 (23), 5601-5604, 2004	136	2004
Applications of neural networks in structure-activity relationships of a small number of molecules IV Tetko, AI Luik, GI Poda Journal of medicinal chemistry 36 (7), 811-814, 1993	122	1993
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 G Senisterra, H Wu, A Allali-Hassani, GA Wasney, D Barsyte-Lovejoy, ... Biochemical Journal 449 (1), 151-159, 2013	118	2013
Structure and mechanism of action of the hydroxy–aryl–aldehyde class of IRE1 endoribonuclease inhibitors M Sanches, NM Duffy, M Talukdar, N Thevakumaran, D Chiovitti, ... Nature communications 5 (1), 1-16, 2014	96	2014
Molecular modelling of the ORL1 receptor and its complex with nociceptin. CM Topham, L Moulédous, G Poda, B Maigret, JC Meunier Protein engineering 11 (12), 1163-1179, 1998	92	1998
An Allosteric Inhibitor of Protein Arginine Methyltransferase 3 A Siarheyeva, G Senisterra, A Allali-Hassani, A Dong, E Dobrovetsky, ... Structure, 2012	81	2012
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ... Bioorganic & Medicinal Chemistry Letters 19 (16), 4882-4884, 2009	61	2009
Condensation-driven assembly of boron-containing bis (heteroaryl) motifs using a linchpin approach S Adachi, SK Liew, CF Lee, A Lough, Z He, JDS Denis, G Poda, AK Yudin Organic letters 17 (22), 5594-5597, 2015	60	2015
A new, improved hybrid scoring function for molecular docking and scoring based on AutoDock and AutoDock Vina VY Tanchuk, VO Tanin, AI Vovk, G Poda Chemical biology & drug design 87 (4), 618-625, 2016	59	2016
Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1) M Getlik, D Smil, C Zepeda-Velazquez, Y Bolshan, G Poda, H Wu, A Dong, ... Journal of medicinal chemistry 59 (6), 2478-2496, 2016	56	2016
Reconstitution and characterization of eukaryotic N6-threonylcarbamoylation of tRNA using a minimal enzyme system LCK Wan, DYL Mao, D Neculai, J Strecker, D Chiovitti, I Kurinov, G Poda, ... Nucleic acids research 41 (12), 6332-6346, 2013	55	2013
HIV-1 reverse transcriptase inhibitor design using artificial neural networks IV Tetko, VY Tanchuk, NP Chentsova, SV Antonenko, GI Poda, VP Kukhar, ... Journal of Medicinal Chemistry 37 (16), 2520-2526, 1994	55	1994
Benzothiophene inhibitors of MK2. Part 1: Structure–activity relationships, assessments of selectivity and cellular potency DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ... Bioorganic & Medicinal Chemistry Letters 19 (16), 4878-4881, 2009	52	2009
Synthesis, optimization, and evaluation of novel small molecules as antagonists of WDR5-MLL interaction Y Bolshan, M Getlik, E Kuznetsova, GA Wasney, T Hajian, G Poda, ... ACS medicinal chemistry letters 4 (3), 353-357, 2013	47	2013

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow this author

Cited by

Co-authors